Ketamine is unusual among anesthetics: it opens airways instead of risking spasm
If you have asthma and you have ever needed surgery, you may have noticed your anesthesiologist asking pointed questions about your inhaler use, your most recent exacerbation, and how often you reach for albuterol in a typical week. That screening exists because most anesthetic agents either depress breathing, irritate the airway, or in some cases provoke bronchospasm. The conversation about asthma in an anesthesia setting is not paranoia. It is preparation.
Ketamine sits in an unusual position in this conversation. Where many anesthetics carry caution flags around reactive airway disease, ketamine is one of the few that has been used because a patient has an active asthma problem. In hospital intensive care units, ketamine has been part of the toolkit for severe asthma exacerbations not responding to standard therapy for decades. The reason is straightforward pharmacology: ketamine relaxes airway smooth muscle.
This article is for asthmatic patients considering outpatient ketamine therapy for mental health or chronic pain. It is not a clinical recommendation to use ketamine for asthma itself. The point is narrower and more practical: when you are screening yourself against the list of conditions that might rule out ketamine therapy, asthma is not the disqualifier you might expect it to be. Active, poorly controlled asthma changes the conversation. Well-controlled asthma usually does not.
The mechanism: catecholamine release, smooth-muscle relaxation, and indirect anti-inflammatory effects
Ketamine produces bronchodilation through several overlapping mechanisms, well described in the anesthesia literature. A widely cited 2013 review by Goyal and Agrawal in the Indian Journal of Critical Care Medicine summarized the pathways: ketamine triggers catecholamine release (which acts on beta-2 receptors in airway smooth muscle the same way albuterol does), exerts direct calcium-mediated smooth-muscle relaxation, and has vagal-mediated effects that further reduce airway tone. In ventilated severe asthmatics, this combination has been reported to lower peak inspiratory pressures and improve gas exchange.
The implication matters in plain English: ketamine acts on airway smooth muscle in roughly the same physiologic direction as your rescue inhaler. That is the opposite of the assumption many patients arrive with. The fear that an anesthetic-class drug will trigger an attack is reasonable in the abstract; it is just not what the asthma-specific data on ketamine shows.
None of this means ketamine treats asthma at the doses we use for mental health or chronic pain. The hospital protocols that exploit ketamine's bronchodilator effect run at higher, anesthetic doses in monitored ICU settings. Outpatient infusion clinics like ours use sub-anesthetic doses, where the airway effects are present but unlikely to be clinically dramatic. The relevant point for screening is that the direction of effect is favorable, not adverse.
How it has been used for severe asthma in hospitals
The evidence base in critical care is not large by cardiology standards, but it has accumulated across decades. A 2022 systematic review by La Via and colleagues in the European Journal of Clinical Pharmacology evaluated ketamine in severe asthma exacerbations and concluded that the existing literature was heterogeneous and did not yet support routine use; reviewers across this space have observed plausible adjunctive benefit in case series alongside the call for better trials.
A 2023 pediatric review by Binsaeedu and colleagues published in Cureus reached similar conclusions for children presenting with acute asthma exacerbations not responding to first-line treatment. The review confirmed bronchodilator efficacy as an adjunct and noted that the most commonly reported side effect was an increase in tracheobronchial secretions—a recognized ketamine effect that, at anesthetic doses in intubated patients, is managed with antisialagogues and suctioning.
These hospital uses are explicitly off-label. Ketamine is FDA-approved as an anesthetic; its use for status asthmaticus, for psychiatric conditions, and for chronic pain are all off-label applications supported by clinical evidence and clinical experience rather than FDA labeling. We will return to the off-label point below.
What this means for outpatient mental-health ketamine therapy
For someone considering ketamine therapy for depression, PTSD, anxiety, or a chronic pain condition, the asthma question shifts from "is this safe at all" to "what is your asthma doing right now." Two things follow from the bronchodilator pharmacology. First, ketamine is not contraindicated in well-controlled asthma in any of the major outpatient ketamine practice guidelines. Second, the routine medical screening any reputable clinic performs is still required, because the relevant variable is asthma control, not asthma diagnosis.
The Cohen et al. 2018 consensus guidelines published jointly by ASRA, AAPM, and ASA on the use of intravenous ketamine for chronic pain explicitly classify a small set of cardiovascular and active psychiatric conditions as relative contraindications. Stable, well-controlled asthma is not on that list. Active, severe pulmonary disease that is poorly compensated is the type of situation those guidelines flag for caution, regardless of the underlying diagnosis. The principle is general: how decompensated is the patient today, not what does their problem list say.
This is why our intake conversation goes beyond a yes/no checkbox. Our safety screening is designed to surface the specifics that matter: how often you use a rescue inhaler, whether you are on a controller medication, when you last had an exacerbation, whether you have ever been hospitalized or intubated for asthma, and what your usual peak flow looks like. Those answers tell us much more than the diagnosis label alone.
Controlled vs. active asthma: the screening distinction
Most asthmatic patients we see fall into the well-controlled category. They take a daily controller medication, use a rescue inhaler infrequently, have not been to an emergency department for asthma in years, and do not have to think about their breathing in any given hour. For this group, ketamine therapy proceeds the same way it would for a non-asthmatic patient, with the additional step of having a rescue inhaler in the room and on the chart.
The screening picture changes if any of the following are true:
- You are in or recently coming out of an exacerbation. If you have been wheezing this week, increased your inhaler use noticeably, or had a course of oral steroids in the last month, that is a reason to delay—not cancel—treatment until your baseline returns.
- You have a history of intubation or ICU admission for asthma. This does not rule out ketamine therapy. It does mean the conversation is more thorough, and we may coordinate with your pulmonologist before booking.
- Your asthma is poorly controlled by your own description. Daily rescue inhaler use, frequent night symptoms, or activity limitation are signals that the underlying disease needs attention before adding any new medical intervention. We will ask you to optimize control with your prescribing provider first.
- You have a known sensitivity to anesthetic agents. Some patients have had bad reactions to specific anesthetics in past surgeries. We document those reactions, look up which agents were involved, and screen accordingly.
None of this is unusual. Anesthesiologists run this calculus before any procedure. The reason we put the criteria in writing for asthmatic patients specifically is that the bronchodilator story tends to surprise people, and the surprise can swing in either direction—some patients assume asthma rules them out, others assume the favorable pharmacology means screening is unnecessary. Both assumptions are wrong.
Increased secretions and other practical considerations
The most commonly cited adverse airway effect of ketamine in the asthma literature is an increase in tracheobronchial secretions. In intubated ICU patients on anesthetic-dose ketamine, this matters and is managed with standard medications and suctioning. In outpatient sub-anesthetic infusions for mental health and pain, this is a much smaller phenomenon. Most patients do not notice it. A few report a sense of mild throat-clearing or a slightly increased need to swallow during the infusion, which resolves shortly after the session ends.
If a patient with reactive airways does experience noticeable secretions or tightness, our protocol allows us to slow or pause the infusion, reposition, and use the patient's own rescue inhaler if appropriate. Marla Peterson, CRNA, is in the room and provides anesthesia-level monitoring throughout the session, including continuous pulse oximetry. A CRNA's training is built around exactly this kind of airway awareness, which is part of why we structure infusion sessions the way we do.
Other practical considerations for asthmatic patients:
- Bring your rescue inhaler to every session. Even if you have not needed it in months. We want it available, the same way we want any patient's regular emergency medications available.
- Use your controller medication as prescribed on the day of treatment. Do not skip your usual inhaled corticosteroid or combination inhaler because of the appointment.
- Tell us if you have had a respiratory infection in the previous two weeks. Viral infections are the most common trigger for asthma exacerbations and can shift control significantly.
- Avoid scheduling treatment during peak allergy weeks if you have allergic asthma and your control degrades seasonally. If spring or fall reliably worsens your asthma, plan around it.
What we ask asthmatic patients before booking
The screening conversation is short, specific, and aimed at surfacing the variables that matter. Expect us to ask: how often you use a rescue inhaler in a typical week, what controller medications you take and at what dose, when you last had an asthma exacerbation requiring oral steroids or an emergency visit, whether you have ever been hospitalized or intubated for asthma, what triggers you know about, and whether your pulmonologist or primary care provider has expressed any reservation about you receiving anesthesia or sedation.
For most asthmatic patients, this conversation lasts a few minutes and ends with a green light to proceed. For a small number, it ends with a recommendation to optimize control with the prescribing clinician before booking, or to coordinate care with a pulmonologist. We will never ask you to start, stop, or change your asthma medications. Talk to your prescribing provider about that. Our role is to make sure the screen is honest and the day-of plan is safe.
Ketamine is FDA-approved as an anesthetic; its use for depression, PTSD, anxiety, and chronic pain is off-label. The clinical evidence supporting these uses is substantial, but the regulatory point matters and we name it clearly. A first infusion is approached deliberately, with full informed consent, and you can stop the conversation at any time. Our safety page walks through the broader screening framework.
Cost is part of an honest conversation too. Sessions are $475 each, and most patients pay out of pocket because insurance coverage for off-label IV ketamine remains limited. We are transparent about this from the first phone call.
Research suggests that for the right candidate, ketamine can produce meaningful and durable improvement in conditions that have been difficult to treat with conventional approaches. Studies indicate that asthma, properly controlled, does not change that picture. The data shows the airway effect runs favorably; the screening still matters because the variable is control, not diagnosis.